Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 10 | 2026 | 704 | 3.560 |
Why?
|
| Brazil | 23 | 2025 | 103 | 1.760 |
Why?
|
| Pneumonectomy | 5 | 2026 | 130 | 1.660 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 593 | 1.450 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 325 | 1.390 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2026 | 184 | 1.210 |
Why?
|
| Antihypertensive Agents | 4 | 2019 | 179 | 1.160 |
Why?
|
| Health Expenditures | 3 | 2020 | 121 | 1.020 |
Why?
|
| Time-to-Treatment | 2 | 2026 | 134 | 1.010 |
Why?
|
| Cost Sharing | 4 | 2020 | 15 | 0.940 |
Why?
|
| Diabetes Mellitus | 6 | 2022 | 555 | 0.910 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2025 | 127 | 0.840 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 801 | 0.830 |
Why?
|
| Retrospective Studies | 18 | 2026 | 6859 | 0.830 |
Why?
|
| Healthcare Disparities | 2 | 2026 | 407 | 0.820 |
Why?
|
| Pharmaceutical Services | 3 | 2018 | 33 | 0.740 |
Why?
|
| Interrupted Time Series Analysis | 6 | 2022 | 30 | 0.680 |
Why?
|
| Commerce | 2 | 2019 | 58 | 0.660 |
Why?
|
| Esophagectomy | 3 | 2026 | 53 | 0.650 |
Why?
|
| Drug Costs | 3 | 2017 | 55 | 0.650 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 225 | 0.650 |
Why?
|
| Health Policy | 4 | 2019 | 191 | 0.640 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 526 | 0.630 |
Why?
|
| Hypertension | 4 | 2020 | 612 | 0.620 |
Why?
|
| Esophageal Neoplasms | 3 | 2026 | 94 | 0.620 |
Why?
|
| Financing, Government | 1 | 2020 | 31 | 0.620 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 106 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1656 | 0.590 |
Why?
|
| Smoking | 1 | 2024 | 861 | 0.590 |
Why?
|
| Pharmaceutical Preparations | 3 | 2015 | 120 | 0.570 |
Why?
|
| Aged | 17 | 2026 | 14945 | 0.570 |
Why?
|
| Drug Prescriptions | 2 | 2025 | 164 | 0.570 |
Why?
|
| Delivery of Health Care | 4 | 2026 | 433 | 0.560 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 526 | 0.540 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 23 | 0.530 |
Why?
|
| Humans | 41 | 2026 | 65095 | 0.530 |
Why?
|
| Middle Aged | 19 | 2026 | 18254 | 0.520 |
Why?
|
| Female | 23 | 2026 | 33997 | 0.520 |
Why?
|
| Drug Industry | 1 | 2017 | 41 | 0.510 |
Why?
|
| Male | 20 | 2026 | 31014 | 0.480 |
Why?
|
| Incidence | 5 | 2025 | 1418 | 0.430 |
Why?
|
| Education, Continuing | 1 | 2014 | 24 | 0.420 |
Why?
|
| Capacity Building | 1 | 2014 | 23 | 0.420 |
Why?
|
| Insurance, Health | 1 | 2015 | 151 | 0.420 |
Why?
|
| Neoplasm Staging | 3 | 2026 | 544 | 0.420 |
Why?
|
| Medication Adherence | 1 | 2015 | 199 | 0.420 |
Why?
|
| Education, Distance | 1 | 2014 | 35 | 0.410 |
Why?
|
| National Health Programs | 4 | 2019 | 20 | 0.390 |
Why?
|
| Postoperative Complications | 5 | 2026 | 1320 | 0.380 |
Why?
|
| Frailty | 2 | 2026 | 129 | 0.370 |
Why?
|
| Acute Disease | 1 | 2013 | 663 | 0.360 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 169 | 0.330 |
Why?
|
| Health Personnel | 1 | 2014 | 385 | 0.310 |
Why?
|
| Primary Health Care | 2 | 2022 | 721 | 0.300 |
Why?
|
| Risk Factors | 6 | 2026 | 5422 | 0.300 |
Why?
|
| Databases, Factual | 4 | 2026 | 882 | 0.300 |
Why?
|
| Malaria | 1 | 2011 | 158 | 0.290 |
Why?
|
| Adult | 10 | 2025 | 17351 | 0.290 |
Why?
|
| Drugs, Essential | 2 | 2018 | 2 | 0.280 |
Why?
|
| Pandemics | 2 | 2025 | 675 | 0.270 |
Why?
|
| Attitude of Health Personnel | 2 | 2014 | 627 | 0.250 |
Why?
|
| Drugs, Generic | 3 | 2019 | 19 | 0.250 |
Why?
|
| Honduras | 3 | 2015 | 3 | 0.250 |
Why?
|
| Guatemala | 3 | 2015 | 4 | 0.250 |
Why?
|
| Quality Indicators, Health Care | 2 | 2026 | 346 | 0.250 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1280 | 0.250 |
Why?
|
| Nicaragua | 3 | 2015 | 17 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 767 | 0.230 |
Why?
|
| United States | 5 | 2026 | 8093 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2026 | 102 | 0.230 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 2703 | 0.220 |
Why?
|
| Prevalence | 3 | 2024 | 1439 | 0.220 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2025 | 62 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2026 | 415 | 0.220 |
Why?
|
| Thoracic Surgery | 2 | 2025 | 80 | 0.220 |
Why?
|
| Politics | 1 | 2025 | 38 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 70 | 0.210 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 36 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 1 | 2026 | 252 | 0.200 |
Why?
|
| Sex Distribution | 1 | 2024 | 252 | 0.200 |
Why?
|
| Chronic Disease | 2 | 2018 | 741 | 0.200 |
Why?
|
| Age Distribution | 1 | 2024 | 262 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2024 | 155 | 0.200 |
Why?
|
| Quality Improvement | 2 | 2026 | 464 | 0.190 |
Why?
|
| Fees, Pharmaceutical | 2 | 2015 | 5 | 0.190 |
Why?
|
| Smokers | 1 | 2023 | 117 | 0.190 |
Why?
|
| Anti-Infective Agents | 1 | 2024 | 152 | 0.190 |
Why?
|
| Societies, Medical | 1 | 2025 | 400 | 0.190 |
Why?
|
| Overweight | 1 | 2024 | 257 | 0.190 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 7 | 0.180 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 7 | 0.180 |
Why?
|
| Robotics | 1 | 2022 | 86 | 0.170 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2023 | 110 | 0.170 |
Why?
|
| Tuberculosis | 1 | 2024 | 306 | 0.170 |
Why?
|
| Program Evaluation | 2 | 2020 | 493 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 151 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2020 | 33 | 0.160 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 41 | 0.160 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 171 | 0.160 |
Why?
|
| Registries | 1 | 2024 | 913 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2023 | 190 | 0.160 |
Why?
|
| Government Programs | 1 | 2020 | 19 | 0.160 |
Why?
|
| Community Pharmacy Services | 1 | 2019 | 12 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 930 | 0.150 |
Why?
|
| Young Adult | 3 | 2025 | 4810 | 0.150 |
Why?
|
| Public Health | 1 | 2021 | 186 | 0.150 |
Why?
|
| Mass Screening | 1 | 2024 | 696 | 0.140 |
Why?
|
| Longevity | 1 | 2019 | 117 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2022 | 528 | 0.130 |
Why?
|
| Losartan | 1 | 2017 | 19 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 22 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Medicare | 1 | 2021 | 624 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.120 |
Why?
|
| Lung | 1 | 2021 | 962 | 0.120 |
Why?
|
| Drug and Narcotic Control | 1 | 2015 | 27 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2026 | 5606 | 0.110 |
Why?
|
| Americas | 1 | 2014 | 6 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2026 | 5784 | 0.100 |
Why?
|
| Professional Competence | 1 | 2014 | 92 | 0.100 |
Why?
|
| Private Sector | 2 | 2010 | 12 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2026 | 2096 | 0.100 |
Why?
|
| Public Sector | 2 | 2010 | 13 | 0.100 |
Why?
|
| Research | 1 | 2014 | 194 | 0.100 |
Why?
|
| Income | 1 | 2013 | 169 | 0.090 |
Why?
|
| Health Care Surveys | 1 | 2013 | 288 | 0.090 |
Why?
|
| Quality of Life | 1 | 2019 | 1259 | 0.090 |
Why?
|
| Cities | 2 | 2021 | 33 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 991 | 0.080 |
Why?
|
| Infant | 2 | 2025 | 1691 | 0.080 |
Why?
|
| World Health Organization | 1 | 2009 | 35 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2025 | 2059 | 0.070 |
Why?
|
| Adolescent | 2 | 2025 | 6305 | 0.070 |
Why?
|
| Operative Time | 1 | 2026 | 93 | 0.060 |
Why?
|
| Operating Rooms | 1 | 2026 | 59 | 0.060 |
Why?
|
| Hydroxychloroquine | 1 | 2025 | 19 | 0.060 |
Why?
|
| Chloroquine | 1 | 2025 | 56 | 0.060 |
Why?
|
| Ivermectin | 1 | 2025 | 25 | 0.060 |
Why?
|
| Azithromycin | 1 | 2025 | 34 | 0.060 |
Why?
|
| Time Factors | 2 | 2025 | 3762 | 0.060 |
Why?
|
| Propensity Score | 1 | 2025 | 189 | 0.050 |
Why?
|
| Reoperation | 1 | 2025 | 301 | 0.050 |
Why?
|
| Outpatients | 1 | 2025 | 142 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2025 | 497 | 0.050 |
Why?
|
| Stomach | 1 | 2024 | 87 | 0.050 |
Why?
|
| Portugal | 1 | 2023 | 3 | 0.050 |
Why?
|
| State Medicine | 1 | 2023 | 12 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2023 | 12 | 0.050 |
Why?
|
| Comorbidity | 1 | 2026 | 1119 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 110 | 0.050 |
Why?
|
| Length of Stay | 1 | 2026 | 827 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 119 | 0.040 |
Why?
|
| Emergencies | 1 | 2022 | 123 | 0.040 |
Why?
|
| Health Services | 1 | 2021 | 80 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1270 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 386 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 63 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2025 | 1420 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 497 | 0.040 |
Why?
|
| Pharmacies | 1 | 2019 | 36 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2022 | 335 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 327 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 420 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 2618 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 2374 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 727 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2019 | 223 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 2762 | 0.030 |
Why?
|
| Child | 1 | 2025 | 4612 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 43 | 0.030 |
Why?
|
| Suriname | 1 | 2014 | 1 | 0.030 |
Why?
|
| El Salvador | 1 | 2014 | 4 | 0.030 |
Why?
|
| Colombia | 1 | 2014 | 22 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2014 | 23 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 84 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 265 | 0.020 |
Why?
|